LB946 Clinically meaningful responses achieved with tralokinumab in adults with moderate-to-severe atopic dermatitis who did not meet IGA 0/1 at initial 16-week treatment

Abstract

In 2 monotherapy phase 3 studies (ECZTRA 1 and 2) of patients with moderate-to-severe atopic dermatitis (AD) treated with tralokinumab, one of the primary endpoints was IGA 0/1 (clear/almost clear) at Week 16. However, in a heterogeneous disease like AD, other important and clinically meaningful parameters include improvement in signs, symptoms, and/or quality of life. We assessed the impact of tralokinumab on AD signs, symptoms, and quality of life in patients with IGA>1 at Week 16. Partial responders, defined as patients with IGA>1 at Week 16, were included in a post-hoc analysis of ECZTRA 1 and 2.